These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 20678850)

  • 1. Activating and resistance mutations of the epidermal growth factor receptor (EGFR) gene and non-small cell lung cancer: a clinical reality.
    Taus A; Vollmer I; Arriola E
    Arch Bronconeumol; 2011 Feb; 47(2):103-5. PubMed ID: 20678850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of EGFR mutation analysis in non-small cell lung cancer.
    Yamamoto H; Toyooka S; Mitsudomi T
    Lung Cancer; 2009 Mar; 63(3):315-21. PubMed ID: 18760859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.
    Bell DW; Gore I; Okimoto RA; Godin-Heymann N; Sordella R; Mulloy R; Sharma SV; Brannigan BW; Mohapatra G; Settleman J; Haber DA
    Nat Genet; 2005 Dec; 37(12):1315-6. PubMed ID: 16258541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on epidermal growth factor receptor mutations in non-small cell lung cancer.
    Riely GJ; Politi KA; Miller VA; Pao W
    Clin Cancer Res; 2006 Dec; 12(24):7232-41. PubMed ID: 17189394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
    Willmore-Payne C; Holden JA; Layfield LJ
    Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
    Johnson BE; Jänne PA
    Cancer Res; 2005 Sep; 65(17):7525-9. PubMed ID: 16140912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
    Wong KK
    Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.
    Yu Z; Boggon TJ; Kobayashi S; Jin C; Ma PC; Dowlati A; Kern JA; Tenen DG; Halmos B
    Cancer Res; 2007 Nov; 67(21):10417-27. PubMed ID: 17974985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
    Kancha RK; von Bubnoff N; Peschel C; Duyster J
    Clin Cancer Res; 2009 Jan; 15(2):460-7. PubMed ID: 19147750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic mutations of EGFR, ERBB2, ERBB3 and ERBB4 in juxtamembrane activating domains are rare in non-small cell lung cancers.
    Park SW; Chung NG; Han JY; Eom HS; Yoo NJ; Lee SH
    APMIS; 2010 Jan; 118(1):83-4. PubMed ID: 20041876
    [No Abstract]   [Full Text] [Related]  

  • 12. Rare mutations in non-small-cell lung cancer.
    D'Arcangelo M; D'Incecco A; Cappuzzo F
    Future Oncol; 2013 May; 9(5):699-711. PubMed ID: 23647298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [ARMS method verified EGFR gene mutations and its clinical significance in patients with non-small cell lung cancer].
    Xu HY; Hong WL; Xie SS; Pan XD; Bai YH; Lin XY; Chen BC
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2014 Mar; 30(2):158-60. PubMed ID: 25016871
    [No Abstract]   [Full Text] [Related]  

  • 14. Decoding the EGFR mutation-induced drug resistance in lung cancer treatment by local surface geometric properties.
    Ma L; Wang DD; Huang Y; Wong MP; Lee VH; Yan H
    Comput Biol Med; 2015 Aug; 63():293-300. PubMed ID: 25035232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma.
    Mohapatra PR; Punatar S; Prabhash K
    Eur Respir J; 2012 Jun; 39(6):1550-1; author reply 1551. PubMed ID: 22654017
    [No Abstract]   [Full Text] [Related]  

  • 16. Tissue Is the Issue for Diagnosis of EGFR T790M Mutation.
    Khan J; Pritchard CC; Martins RG
    J Thorac Oncol; 2016 Jul; 11(7):e91-2. PubMed ID: 27339415
    [No Abstract]   [Full Text] [Related]  

  • 17. What is the true prevalence of EGFR mutations in India?
    Jiwnani S; Karimundackal G; Pramesh CS; Prabhash K
    Lung Cancer; 2011 Dec; 74(3):549. PubMed ID: 21996090
    [No Abstract]   [Full Text] [Related]  

  • 18. Germline mutations predisposing to non-small cell lung cancer.
    Clamon GH; Bossler AD; Abu Hejleh T; Furqan M
    Fam Cancer; 2015 Sep; 14(3):463-9. PubMed ID: 25813228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphological and genetic classification of lung cancer: variation in practice and implications for tailored treatment.
    Cane P; Linklater KM; Nicholson AG; Peake MD; Gosney J
    Histopathology; 2015 Aug; 67(2):216-24. PubMed ID: 25545849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole Brain Radiotherapy for Patients with Non-Small Cell Lung Cancer with EGFR Mutations-Why and When?
    Dziadziuszko R
    J Thorac Oncol; 2016 Oct; 11(10):1604-5. PubMed ID: 27663395
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.